Longitudinal analysis reveals that delayed bystander CD8+ T cell activation and early immune pathology distinguish severe COVID-19 from mild disease.
Bergamaschi L, Mescia F, Turner L, Hanson AL, Kotagiri P, Dunmore BJ, Ruffieux H, De Sa A, Huhn O, Morgan MD, Gerber PP, Wills MR, Baker S, Calero-Nieto FJ, Doffinger R, Dougan G, Elmer A, Goodfellow IG, Gupta RK, Hosmillo M, Hunter K, Kingston N, Lehner PJ, Matheson NJ, Nicholson JK, Petrunkina AM, Richardson S, Saunders C, Thaventhiran JED, Toonen EJM, Weekes MP; Cambridge Institute of Therapeutic Immunology and Infectious Disease-National Institute of Health Research (CITIID-NIHR) COVID BioResource Collaboration; Göttgens B, Toshner M, Hess C, Bradley JR, Lyons PA, Smith KGC.
Bergamaschi L, et al. Among authors: ruffieux h.
Immunity. 2021 Jun 8;54(6):1257-1275.e8. doi: 10.1016/j.immuni.2021.05.010. Epub 2021 May 16.
Immunity. 2021.
PMID: 34051148
Free PMC article.